Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

o received ANA773 at 1600 mg. Anadys expects to present further results from this study later this year and intends to explore partnership opportunities as a potential path to continue the development of ANA773.
  • Reported PK/PD Data for ANA773 in HCV at EASL. In April 2009, the pharmacokinetic (PK) and pharmacodynamic (PD) data from the healthy volunteer portion of the Phase I clinical trial of ANA773 in HCV were reported at the EASL conference. ANA773 was generally well tolerated with no serious adverse events. Plasma drug levels were proportional to dose, and there was a dose-dependent induction of well-recognized interferon dependent biomarkers.
  • Phase I Clinical Trial in Oncology. In order to focus its resources on ANA598, Anadys recently elected to stop enrollment of new patients in the ongoing Phase I oncology trial of ANA773. Anadys plans for currently enrolled patients to continue to receive ANA773 until disease progression is observed and to conclude the trial once all patients reach this point.

    • Webcast of Conference Call

    Anadys will host a conference call at 5:00 pm Eastern Daylight Time today to discuss its second quarter 2009 financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 85411914. The webcast and telephone replay will be available through August 13, 2009.

    About Anadys

    Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
    8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
    9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
    10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
    11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
    (Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
    (Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
    (Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
    Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
    ... Johnson & Johnson (NYSE: JNJ ) ... of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that ... is expected to operate as a stand-alone entity reporting ... Johnson & Johnson , Caring for the world, ...
    ... SUNNYVALE, Calif., Dec. 30 Accuray Incorporated,(Nasdaq: ARAY ... today,that its president and chief executive officer, Euan S. Thomson, ... Healthcare Conference in San,Francisco, on Wednesday, January 14, 2009 at ... A live webcast of the presentation will be available ...
    ... and PHILADELPHIA, Pennsylvania,December 29 Rosetta Genomics, ... molecular diagnostics, announced,today the introduction of its ... now commercially available through Rosetta Genomics CLIA-certified,lab ... To order the test, physicians may contact ...
    Cached Biology Technology:Accuray Incorporated's CEO to Speak at 27th Annual JP Morgan Healthcare Conference 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 3Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 4Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 5
    (Date:6/18/2013)... -- Paris Air Show – Marvin Test Solutions ... leading provider of innovative test solutions for military ... this week at the Paris Air Show ... increasingly complex armament systems with longer lifecycles, industry ... solutions that address legacy system obsolescence. Marvin Test ...
    (Date:6/18/2013)... the University of Calgary,s Faculty of Medicine have discovered ... from harmful bacteria. Platelets, a component of blood typically ... specific bacteria, and upon detection, seal it off from ... published in Nature Immunology this week, provide ... , "The science community has known that platelets do ...
    (Date:6/18/2013)... Kingdom, the Energy Department,s National Renewable Energy Laboratory ... published a paper describing a novel cellulose-degrading enzyme ... , commonly known as the gribble. , ... relatively unique ability to produce their own enzymes ... the biomass they eat. New biomass-degrading enzymes from ...
    Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Immunity mechanism discovered 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2
    ... is available in French . A breakthrough ... and Denmark has uncovered a new gene that could lead ... a better understanding of how this widespread disease develops. ... diabetes, the new gene, called Insulin Receptor Substrate 1 (IRS1), doesn,t ...
    ... risk of bowel cancer has found that 50 percent ... implications. "This indicates that people have a significant ... have potentially life saving genetic testing," says co-lead author ... Centre for Women,s Health in Society. The population-based ...
    ... Taylor Chair of Chemistry Barry Dellinger was recently awarded a ... Health Sciences, or NIEHS, to support a Superfund Research Center ... health. It is the only center ever awarded by this ... school of public health. "This grant is the result of ...
    Cached Biology News:Diabetes advance: Researchers find gene that causes resistance to insulin 2Diabetes advance: Researchers find gene that causes resistance to insulin 3Fear of insurance rejection deters potentially life saving genetic tests for bowel cancer 2LSU receives $3.6 million to fund center studying hazardous waste cleanup and health impacts 2
    Request Info...
    Sterile, individually wrapped, 4mm Cuvettes...
    versican (H-56)...
    ... S1 Nuclease degrades single-stranded DNA and ... Double-stranded nucleic acids (DNA:DNA, DNA:RNA or ... with extremely high concentrations of enzyme ... remove single-stranded termini from double-stranded DNA ...
    Biology Products: